# US 10,479,822 B2 · Pharmaceutical compositions containing, as active ingredient, granulocyte-colony stimulating factor mutant protein or transferrin fusion protein thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,479,822 B2 - Document ID: US10479822B2 - Status: Granted - Kind: B2 - Application number: 15/327,838 - Filed: 2014-11-21 - Published: 2017-08-03 - Granted: 2019-11-19 - Earliest claimed: 2014-07-23 - Assignees: Supex Bnp Co., Ltd. - Applicants: Supex Bnp Co., Ltd. - Inventors: Jeong-Hyeok Yoon; Byung-Ha Chang; Bong-Seok Jin; Ji Young Bae; Soon Nam Kim; Kyeong Su Park; Yeong kyu Park; Hanjo Kim; Youngju Seo; Wooseong Jeong; KyungTae Kang - Web page: https://patentgrep.com/patent/US10479822B2 ## CPC - C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61P 35/00: Antineoplastic agents - C07K 14/79: Transferrins, e.g. lactoferrins, ovotransferrins - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K 2319/00: Fusion polypeptide - C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present invention relates to a fusion protein in which transferrin is peptide-bonded to a terminal of a granulocyte-colony stimulating factor (G-CSF) protein or a G-CSF mutant protein in which the 116th threonine is substituted with cysteine in the amino acid sequence of the G-CSF. Specifically, the granulocyte-colony stimulating factor (G-CSF) mutant protein of the present invention or the transferrin fusion protein thereof displays a significantly increased specific activity and blood stability, compared with the conventional human G-CSF, and has a higher purification efficiency than the conventional PEGylated G-CSF characterized by the extended half-life, so that it can be advantageously used for preventing or treating ischemic diseases or neutropenia. ## Claims ### Claim 1 A fusion protein in which transferrin is peptide-bonded to a G-CSF (granulocyte-colony stimulating factor) mutant protein in which the 116th threonine is substituted with a cysteine. ### Claim 2 (depends on 1) The fusion protein according to claim 1, wherein the transferrin has the deletion of a signal peptide at the amino terminal region. ### Claim 3 (depends on 2) A method, comprising administering the fusion protein of claim 2 to a subject. ### Claim 4 (depends on 1) The fusion protein according to claim 1, wherein the substituted cysteine forms a disulfide bond with the 17th cysteine of the G-CSF mutant protein. ### Claim 5 (depends on 4) A method, comprising administering the fusion protein of claim 4 to a subject. ### Claim 6 (depends on 1) A method, comprising administering the fusion protein of claim 1 to a subject. ### Claim 7 A fusion protein, comprising a transferrin protein that is peptide-bonded to a G-CSF (granulocyte-colony stimulating factor) mutant protein in which the 116th threonine is a substituted with a cysteine. ### Claim 8 (depends on 7) The fusion protein according to claim 7, wherein the transferrin protein does not have a native signal peptide at the amino terminal region. ### Claim 9 (depends on 7) A method, comprising administering the fusion protein of claim 7 to a subject. ### Claim 10 A fusion protein, comprising: a G-CSF (granulocyte-colony stimulating factor) mutant protein in which the 116th threonin is substituted with a cysteine; and a transferrin protein peptide-bonded to the G-CSF mutant protein, wherein the transferrin has deletion of a signal peptide at the amino terminal region. ### Claim 11 (depends on 10) A method, comprising administering the fusion protein of claim 10 to a subject.